![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JJ Rutter and SB Auerbach
Department of Biological Sciences, Rutgers University, Piscataway, New Jersey.
The effect of acute uptake inhibition on serotonin (5-HT) in the rat central nervous system was monitored by using in vivo dialysis. Peripheral administration of the selective 5-HT uptake blocker, fluoxetine, caused a dose-dependent increase in extracellular 5-HT in both the diencephalon and the striatum. Administration of fluoxetine or sertraline, another selective 5-HT uptake inhibitor, caused a prolonged (24 hr) increase in 5-HT and decrease in 5-hydroxyindoleacetic acid. In addition, fluoxetine and sertraline attenuated the 5-HT releasing effect of fenfluramine administered 24 hr later. Local infusion of fluoxetine into the diencephalon caused an increase in 5-HT that was twice as large as the effect of peripheral injection. Peripheral fluoxetine, by enhancing extracellular 5-HT in the raphe, probably resulted in activation of somatodendritic autoreceptors and inhibition of 5-HT neuronal discharge. Thus, the increase in 5-HT in the diencephalon after peripheral fluoxetine presumably reflected a balance between decreased release and inhibition of reuptake. In support of this, after first infusing fluoxetine into the diencephalon to maximally block reuptake, peripheral injection of the uptake inhibitor caused a decrease in 5-HT.
This article has been cited by other articles:
|
|
 |
|
  R. Tao, Z. Ma, and S. B. Auerbach Differential Effect of Local Infusion of Serotonin Reuptake Inhibitors in the Raphe versus Forebrain and the Role of Depolarization-Induced Release in Increased Extracellular Serotonin J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 571 - 579. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Pineyro and P. Blier Autoregulation of Serotonin Neurons: Role in Antidepressant Drug Action Pharmacol. Rev., September 1, 1999; 51(3): 533 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kim, V. Adipudi, M. Shibayama, S. Giszter, A. Tessler, M. Murray, and K. J. Simansky Direct Agonists for Serotonin Receptors Enhance Locomotor Function in Rats that Received Neural Transplants after Neonatal Spinal Transection J. Neurosci., July 15, 1999; 19(14): 6213 - 6224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gundlah, K. F. Martin, D. J. Heal, and S. B. Auerbach In Vivo Criteria To Differentiate Monoamine Reuptake Inhibitors from Releasing Agents: Sibutramine Is a Reuptake Inhibitor J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 581 - 591. [Abstract] [Full Text]
|
|
|
|
|
|
L. G. Kirby and I. Lucki Interaction Between the Forced Swimming Test and Fluoxetine Treatment on Extracellular 5-Hydroxytryptamine and 5-Hydroxyindoleacetic Acid in the Rat J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 967 - 976. [Abstract] [Full Text]
|
|
|
|
 |
|
 P.J. Cowen and P.A. Sargent Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission J Psychopharmacol, January 1, 1997; 11(4): 345 - 348. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
